StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Kalaris Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Kalaris Therapeutics's ebitda for the twelve months ending Dec 31, 2023 was -$199.50M. For fiscal 2023 it was -$199.50M. The highest annual figure on record is -$26.68M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$199.50M–
FY2022Dec 31, 2022-$170.48M–
FY2021Dec 31, 2021-$169.63M–
FY2020Dec 31, 2020-$71.24M–
FY2019Dec 31, 2019-$26.68M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$62.27M–
Q3 FY2023Sep 30, 2023-$46.88M–
Q2 FY2023Jun 30, 2023-$47.22M–
Q1 FY2023Mar 31, 2023-$43.15M–
Q4 FY2022Dec 31, 2022-$40.35M–
Q3 FY2022Sep 30, 2022-$42.87M–
Q2 FY2022Jun 30, 2022-$44.54M–
Q1 FY2022Mar 31, 2022-$42.73M–
Q4 FY2021Dec 31, 2021-$55.70M–
Q3 FY2021Sep 30, 2021-$45.46M–
Q2 FY2021Jun 30, 2021-$37.62M–
Q1 FY2021Mar 31, 2021-$30.85M–
Q4 FY2020Dec 31, 2020-$25.40M–
Q3 FY2020Sep 30, 2020-$23.88M–
Q2 FY2020Jun 30, 2020-$12.13M–
Q1 FY2020Mar 31, 2020-$9.82M–

More Kalaris Therapeutics figures

See a number that looks wrong?